vs

Side-by-side financial comparison of Alight, Inc. (ALIT) and Royalty Pharma plc (RPRX). Click either name above to swap in a different company.

Alight, Inc. is the larger business by last-quarter revenue ($653.0M vs $622.0M, roughly 1.0× Royalty Pharma plc). Royalty Pharma plc runs the higher net margin — 34.4% vs -142.7%, a 177.2% gap on every dollar of revenue. On growth, Royalty Pharma plc posted the faster year-over-year revenue change (4.8% vs -4.0%). Over the past eight quarters, Alight, Inc.'s revenue compounded faster (8.1% CAGR vs 4.6%).

Alight Solutions is an American information technology and consulting company that provides cloud-based systems, outsourcing and consultancy related to human resource. They provide platforms and outsourcing for large companies to manage their human capital this includes health benefit administration, financial management and retirement planning.

Acceleron Pharma, Inc. is an American clinical stage biopharmaceutical company based in Cambridge, Massachusetts with a broad focus on developing medicines that regulate the transforming growth factor beta (TGF-β) superfamily of proteins, which play fundamental roles in the growth and repair of cells and tissues such as red blood cells, muscle, bone, and blood vessels.

ALIT vs RPRX — Head-to-Head

Bigger by revenue
ALIT
ALIT
1.0× larger
ALIT
$653.0M
$622.0M
RPRX
Growing faster (revenue YoY)
RPRX
RPRX
+8.7% gap
RPRX
4.8%
-4.0%
ALIT
Higher net margin
RPRX
RPRX
177.2% more per $
RPRX
34.4%
-142.7%
ALIT
Faster 2-yr revenue CAGR
ALIT
ALIT
Annualised
ALIT
8.1%
4.6%
RPRX

Income Statement — Q4 FY2025 vs Q4 FY2025

Metric
ALIT
ALIT
RPRX
RPRX
Revenue
$653.0M
$622.0M
Net Profit
$-932.0M
$214.2M
Gross Margin
36.8%
Operating Margin
-114.9%
62.4%
Net Margin
-142.7%
34.4%
Revenue YoY
-4.0%
4.8%
Net Profit YoY
-11750.0%
2.9%
EPS (diluted)
$-1.77
$0.49

Green = leading value per metric. Periods may differ when fiscal calendars don't align.

8-Quarter Revenue & Profit Trend

Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.

Revenue
ALIT
ALIT
RPRX
RPRX
Q4 25
$653.0M
$622.0M
Q3 25
$533.0M
$609.3M
Q2 25
$528.0M
$578.7M
Q1 25
$548.0M
$568.2M
Q4 24
$680.0M
$593.6M
Q3 24
$555.0M
$564.7M
Q2 24
$538.0M
$537.3M
Q1 24
$559.0M
$568.0M
Net Profit
ALIT
ALIT
RPRX
RPRX
Q4 25
$-932.0M
$214.2M
Q3 25
$-1.1B
$288.2M
Q2 25
$-1.1B
$30.2M
Q1 25
$-25.0M
$238.3M
Q4 24
$8.0M
$208.2M
Q3 24
$-74.0M
$544.0M
Q2 24
$23.0M
$102.0M
Q1 24
$-114.0M
$4.8M
Gross Margin
ALIT
ALIT
RPRX
RPRX
Q4 25
36.8%
Q3 25
33.4%
Q2 25
33.3%
Q1 25
31.2%
Q4 24
39.9%
Q3 24
31.4%
Q2 24
31.0%
Q1 24
32.6%
Operating Margin
ALIT
ALIT
RPRX
RPRX
Q4 25
-114.9%
62.4%
Q3 25
-248.0%
70.1%
Q2 25
-191.3%
36.3%
Q1 25
-1.5%
94.0%
Q4 24
6.5%
60.9%
Q3 24
-7.6%
Q2 24
-9.7%
50.2%
Q1 24
-7.2%
-13.0%
Net Margin
ALIT
ALIT
RPRX
RPRX
Q4 25
-142.7%
34.4%
Q3 25
-200.2%
47.3%
Q2 25
-203.2%
5.2%
Q1 25
-4.6%
41.9%
Q4 24
1.2%
35.1%
Q3 24
-13.3%
96.3%
Q2 24
4.3%
19.0%
Q1 24
-20.4%
0.8%
EPS (diluted)
ALIT
ALIT
RPRX
RPRX
Q4 25
$-1.77
$0.49
Q3 25
$-2.02
$0.67
Q2 25
$-2.03
$0.07
Q1 25
$-0.05
$0.55
Q4 24
$0.02
$0.46
Q3 24
$-0.14
$1.21
Q2 24
$0.04
$0.23
Q1 24
$-0.21
$0.01

Balance Sheet & Financial Strength

Snapshot of each company's liquidity, leverage and book value from the latest quarter.

Metric
ALIT
ALIT
RPRX
RPRX
Cash + ST InvestmentsLiquidity on hand
$273.0M
$618.7M
Total DebtLower is stronger
$2.0B
$9.0B
Stockholders' EquityBook value
$1.0B
$9.7B
Total Assets
$4.6B
$19.6B
Debt / EquityLower = less leverage
1.92×
0.92×

8-quarter trend — quarters aligned by calendar period.

Cash + ST Investments
ALIT
ALIT
RPRX
RPRX
Q4 25
$273.0M
$618.7M
Q3 25
$205.0M
$938.9M
Q2 25
$227.0M
$631.9M
Q1 25
$223.0M
$1.1B
Q4 24
$343.0M
$929.0M
Q3 24
$300.0M
$950.1M
Q2 24
$183.0M
$1.8B
Q1 24
$256.0M
$843.0M
Total Debt
ALIT
ALIT
RPRX
RPRX
Q4 25
$2.0B
$9.0B
Q3 25
$2.0B
$8.9B
Q2 25
$2.0B
$8.0B
Q1 25
$2.0B
$7.6B
Q4 24
$2.0B
$7.6B
Q3 24
$2.0B
$7.6B
Q2 24
$2.8B
$7.6B
Q1 24
$2.8B
$6.1B
Stockholders' Equity
ALIT
ALIT
RPRX
RPRX
Q4 25
$1.0B
$9.7B
Q3 25
$2.0B
$9.6B
Q2 25
$3.1B
$9.5B
Q1 25
$4.2B
$9.8B
Q4 24
$4.3B
$10.3B
Q3 24
$4.3B
$10.3B
Q2 24
$4.5B
$9.8B
Q1 24
$4.5B
$9.9B
Total Assets
ALIT
ALIT
RPRX
RPRX
Q4 25
$4.6B
$19.6B
Q3 25
$5.5B
$19.3B
Q2 25
$6.8B
$18.3B
Q1 25
$7.9B
$17.6B
Q4 24
$8.2B
$18.2B
Q3 24
$8.3B
$18.0B
Q2 24
$10.5B
$17.7B
Q1 24
$10.7B
$16.1B
Debt / Equity
ALIT
ALIT
RPRX
RPRX
Q4 25
1.92×
0.92×
Q3 25
1.00×
0.93×
Q2 25
0.65×
0.84×
Q1 25
0.48×
0.78×
Q4 24
0.47×
0.74×
Q3 24
0.47×
0.74×
Q2 24
0.62×
0.78×
Q1 24
0.62×
0.62×

Cash Flow & Capital Efficiency

How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.

Metric
ALIT
ALIT
RPRX
RPRX
Operating Cash FlowLast quarter
$124.0M
$827.1M
Free Cash FlowOCF − Capex
$99.0M
FCF MarginFCF / Revenue
15.2%
Capex IntensityCapex / Revenue
3.8%
Cash ConversionOCF / Net Profit
3.86×
TTM Free Cash FlowTrailing 4 quarters
$250.0M

8-quarter trend — quarters aligned by calendar period.

Operating Cash Flow
ALIT
ALIT
RPRX
RPRX
Q4 25
$124.0M
$827.1M
Q3 25
$77.0M
$702.6M
Q2 25
$86.0M
$364.0M
Q1 25
$73.0M
$596.1M
Q4 24
$118.0M
$742.5M
Q3 24
$-24.0M
$703.6M
Q2 24
$58.0M
$658.2M
Q1 24
$100.0M
$664.6M
Free Cash Flow
ALIT
ALIT
RPRX
RPRX
Q4 25
$99.0M
Q3 25
$49.0M
Q2 25
$58.0M
Q1 25
$44.0M
Q4 24
$92.0M
Q3 24
$-52.0M
Q2 24
$22.0M
Q1 24
$69.0M
FCF Margin
ALIT
ALIT
RPRX
RPRX
Q4 25
15.2%
Q3 25
9.2%
Q2 25
11.0%
Q1 25
8.0%
Q4 24
13.5%
Q3 24
-9.4%
Q2 24
4.1%
Q1 24
12.3%
Capex Intensity
ALIT
ALIT
RPRX
RPRX
Q4 25
3.8%
Q3 25
5.3%
Q2 25
5.3%
Q1 25
5.3%
Q4 24
3.8%
Q3 24
5.0%
Q2 24
6.7%
Q1 24
5.5%
Cash Conversion
ALIT
ALIT
RPRX
RPRX
Q4 25
3.86×
Q3 25
2.44×
Q2 25
12.06×
Q1 25
2.50×
Q4 24
14.75×
3.57×
Q3 24
1.29×
Q2 24
2.52×
6.45×
Q1 24
139.10×

Financial Flow Comparison

Revenue → gross profit → operating profit → net profit for each company.

Revenue Breakdown by Segment

ALIT
ALIT

Recurring$607.0M93%
Projects$46.0M7%

RPRX
RPRX

Financial Royalty Assets$592.4M95%
Royalty Income Other$29.6M5%

Related Comparisons